The recommendations drew heavily from the PIANO study, which tracked 2,268 pregnant women with IBD and 1,702 live births. The consortium used formal Grading of Recommendations Assessment, Development, ...

With a fresh endorsement from the FDA, Johnson & Johnson has rounded out Tremfya’s presence in inflammatory bowel disease ...

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...

A Spanish trial finds similar sustained IBD clinical remission rates 1-year post-withdrawal vs maintenance of anti-TNF ...

The 28-year-old defender is now supporting IBD research by the Royal Devon University Healthcare NHS Foundation Trust and the ...

One-day intensive course boosted first-year trainees’ overall confidence in IBD and raised comfort levels in discussing ...

Patients with inflammatory bowel disease had a higher risk for venous thromboembolism after surgery for colorectal cancer ...

Living with inflammatory bowel disease is challenging for anyone, but women face a unique set of complications that extend far beyond the typical digestive symptoms most people associate with ...

Early onset active inflammatory bowel disease (IBD) is associated with significantly higher rates of psychiatric disorders and increased use of psychotropic medications. Patients with IBD exhibit a ...

Both inflammatory bowel disease (IBD) and endometriosis can cause similar symptoms, such as chronic inflammation, suggesting that there may be a link. However, further research is still needed to ...

The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately to severely ...